21st Forum: Breaking into U.S Healthcare Market: Collaborative Partnership Opportunities

November 28, 2022

6:00 PM – 9:30 PM

The Press Lounge - Greenhouse Room, Rooftop 16th Fl

​

New York City is home to the largest public healthcare system in the United States, with world-class private medical centers and a growing robust R&D landscape. Led by $1 billion initiative LifeSci NYC, the City’s investment in life sciences promises to create, produce and deliver dozens of new cures and treatments. This environment is ripe with opportunities for Korean and Korean American healthcare stakeholders to participate and leverage their positions.

A new path towards the future of critical patientcare is forged when physicians, pharmaceutical and medical device innovators, investors, healthcare regulators and policymakers work together globally. The New York Health Forum welcomes today’s healthcare leaders for a stimulating discussion on potential areas of growth and collaboration in 2023 and beyond.

Program

​

6:00-6:20 PM    Welcome Remarks

Sanghee Kim, Minister counselor at Embassy of the Republic of Korea

6:20-6:50 PM    Presentations

KHIDI & KHIDI USA roles in entering the U.S health industry

SoonmahnPark, PhD, President, KHIDI USA

The State of A.I. in New Drug Discovery and Development

Kilyoung Kim, PhD, President, Syntekabio USA

6:50-7:30 PM    Briefings

Introducing KAMPANY and Its Mission

Sanghyun Alex Kim, MD, President of KAMPA (Associate Professor of

Surgery at the Icahn School of Medicine at Mount Sinai)

Opportunities and Challenges for the Korean Pharma Industry

Han S. Bang, US representative, ST Pharm (a Dong-A company)

Introduction to InnoTherapy technology

Peter Lee, Director, InnoTherapyAmerica Inc.

Genomics/Proteomics clinical research service provider

Seung Woo Song, VP, Psomagen

7:30PM -            Networking Dinner

Speaker Biography

Sanghee Kim

Minister counselor at Embassy of the Republic of Korea

Sanghee Kim is a diplomat currently serving as Minister Counselor at the Embassy of the Republic of Korea. With a distinguished career in international relations, Kim has adeptly navigated complex diplomatic landscapes, leveraging expertise in political strategy and cultural diplomacy to foster strong bilateral relationships. His commitment to advancing Korea's interests on the global stage is underscored by a rich background in diplomacy, having held various key positions within the Ministry of Foreign Affairs prior to assuming duties at the embassy. Known for his deep understanding of intergovernmental affairs, he continues to play a pivotal role in strengthening ties between Korea and its international partners while promoting mutual understanding and cooperation.

SoonmahnPark, PhD

PhD, President, KHIDI USA

Dr. Soonmahn Park is a distinguished leader in healthcare innovation and cross-cultural business development, currently serving as the President of KHIDI USA. With a background rooted in scientific expertise and extensive experience in international collaboration, Dr. Park is dedicated to advancing the global impact of the Korean healthcare industry. As President of KHIDI USA, Dr. Park plays a pivotal role in fostering strategic partnerships and facilitating market entry for Korean healthcare companies seeking to expand into the North American market. Leveraging his deep understanding of both Korean and U.S. healthcare landscapes, he provides invaluable guidance and insight to companies looking to navigate regulatory frameworks, adapt their technologies, and establish a presence in the United States. His commitment to driving forward the mission of KHIDI USA underscores his vision for a more interconnected and impactful global healthcare ecosystem.

Kilyoung Kim, PhD

President, KHIDI USA

Kilyoung Kim, PhD, is a distinguished leader in the field of biomedical research and technology, currently serving as President of Syntekabio USA. With a background rooted in advanced scientific inquiry, Kim brings a wealth of expertise to his role, driving innovation at the intersection of artificial intelligence and pharmaceuticals. Under Kim's guidance, Syntekabio has emerged as a trailblazer in AI-driven drug discovery and development. Leveraging cutting-edge technologies such as next-generation sequencing and proprietary AI algorithms like DeepMatcher, the company is revolutionizing the pharmaceutical industry's approach to identifying and designing novel therapeutics.

Sanghyun Alexander Kim, MD

President 2023, KAMPANY | Associate Professor of Surgery, Icahn School of Medicine at Mount Sinai

Dr. Sanghyun (Alex) Kim is an Associate Professor of Surgery at the Icahn School of Medicine at Mount Sinai and the Site Chief of Colon and Rectal Surgery at Mount Sinai Beth Israel, Mount Sinai Downtown-Union Square, and Mount Sinai Morningside. Specializing in robotic, laparoscopic, and trans-anal surgical techniques, Dr. Kim has been instrumental in revitalizing and growing the downtown colorectal surgery program since becoming Site Chief of Mount Sinai Downtown in 2018. As Site Chief of both MSBI and MSM, Dr. Kim is energized to further improve patient experiences by providing seamless care to both our downtown and uptown communities.

  Han S. Bang

US representative, ST Pharm (a Dong-A company)

Han S. Bang serves as the US representative for ST Pharm, a subsidiary of Dong-A, a pioneering pharmaceutical company in Korea. With a comprehensive background in pharmaceuticals and business development, Bang is a key figure in navigating the opportunities and challenges facing the Korean pharma industry. In his role at ST Pharm, Bang focuses on leveraging the company's expertise in manufacturing RNA-based drugs to meet the evolving needs of clients in pharmaceutical development and commercialization. Through top-tier custom manufacturing services for active pharmaceutical ingredients and intermediates, ST Pharm aims to exceed client expectations and contribute to advancements in healthcare. His dedication to fostering partnerships and delivering high-quality solutions underscores ST Pharm's commitment to innovation and excellence in the global pharmaceutical arena.

 Peter Lee

Director, InnoTherapyAmerica Inc.   

Peter Lee is the Director of InnoTherapyAmerica Inc., a dynamic leader at the forefront of healthcare innovation. With a proven track record in bringing cutting-edge technologies to market, he plays a pivotal role in driving the development and expansion of InnoTherapy's innovative products. Under his guidance, InnoTherapy has established itself as a trailblazer in clinical technologies, harnessing the collective passion and talent of its team to create transformative solutions for the global healthcare market. Through strategic research and development efforts, the company has successfully pioneered a range of powerful medical sealant products tailored to address diverse medical needs. Peter Lee continues to spearhead InnoTherapy's mission to revolutionize healthcare through cutting-edge technology and groundbreaking solutions.

Seung Woo Song, 

Vice President, Psomagen

Seung Woo Song serves as the Vice President of Psomagen, a leading provider of genomics and proteomics clinical research services. With a strong background in science and business management, he plays a pivotal role in guiding Psomagen's strategic initiatives and ensuring the delivery of high-quality services to clients worldwide. Under his leadership, Psomagen has established itself as a trusted partner for scientists and clinicians seeking contract research services. The company's laboratories have earned prestigious certifications, including CLIA certification and CAO accreditation, reflecting Psomagen's commitment to maintaining the highest standards of quality and compliance in sample handling and analysis. Seung Woo Song's leadership and expertise position Psomagen as a leader in the genomics and proteomics research landscape, poised to make meaningful contributions to scientific discovery and healthcare innovation.